what genomic assay is best suited for the extended endocrine therapy decision?
Published 4 years ago • 149 plays • Length 0:41Download video MP4
Download video MP3
Similar videos
-
1:28
what role do genomic assays play in the decision to extend endocrine therapy?
-
53:42
guideline updates for extended endocrine therapy decision-making in hr , early-stage breast cancer
-
41:53
guideline updates for extended endocrine therapy decision-making in hr , early-stage breast cancer
-
5:04
standardizing extended endocrine therapy recommendations
-
0:32
news: genomic assay breast cancer index indicates treatment risk
-
6:35
extended endocrine therapy: who will benefit?
-
14:37
genomic testing in breast cancer: what you must know
-
16:19
breast cancer index, extended endocrine therapy | elizabeth ott, pa | 2022 west oncology app updates
-
1:10:36
updates in extended endocrine therapy for hr breast cancer | asco21 & national practice guidelines
-
1:39
utilizing the appropriate tool for extended endocrine therapy decision-making: bci vs oncotype dx
-
4:33
tailorx: genomic test helps identify low-risk women who do not need chemotherapy
-
0:52
the role of bci in extended endocrine therapy decision making
-
3:16
what is breast cancer index?
-
2:34
genomic assays impact treatment decisions in patients with er breast cancer
-
1:40
dr. simon on genomic assays for patients with breast cancer
-
26:38
genomic assays and breast cancer
-
3:22
decision-making impact of the breast cancer index
-
2:47
genomic assays impact treatment decisions in patients with er breast cancer
-
1:50
challenges with patient selection for extended adjuvant endocrine therapy in breast cancer